Bevacizumab in Combination With Radiotherapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme

BACKGROUND. Patients with a newly diagnosed glioblastoma multiforme (GBM) have a high risk of recurrent disease with a dismal outcome despite intensive treatment of sequential surgery and chemoradiotherapy with temozolomide (TMZ), followed by TMZ as a single agent. Bevacizumab (BV) may increase resp...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: van Linde, Myra E., Verhoeff, Joost J.C., Richel, Dirk J., van Furth, Wouter R., Reijneveld, Jaap C., Verheul, Henk M.W., Stalpers, Lukas J.A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2015
Aiheet:
Clinical Trial Results
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319643/
https://ncbi.nlm.nih.gov/pubmed/25582142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0418
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia